LY-2434074 is a selective β-secretase (BACE) inhibitor with an IC50 <100 nM. LY-2434074 can inhibit amyloid-β (Aβ40 and Aβ42) production. LY-2434074 can be used for the research of neurological disease, such as Alzheimer's disease.

5-cis-15(R)-Iloprost (5-cis-15(R)-Ciloprost) is the C-5 cis-isomer and 15(R)-epimer of Iloprost. Iloprost is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research.

BMS-199264 is an inhibitor of F1F0 ATP hydrolase (IC50=0.5 μM) without inhibitory effect on F1F0 ATP synthase. BMS-199264 selectively inhibits ATP decline during ischemia to reduces cardiac necrosis. BMS-199264 also enhances the recovery of contractile function following reperfusion.

COPCP trisodium (Compound 7a) is a potent and selective ecto-5'-nucleotidase CD73 inhibitor. COPCP trisodium blocks CD73-mediated adenosine production, reducing the inhibitory effect of adenosine on immune cells. COPCP trisodium is promising for research of cancers.

Tauroursocholic acid (TUCA) sodium is a taurine-conjugated form of the bile acid ursocholic acid and the 7β-hydroxy epimer of Taurocholic acid. Tauroursocholic acid sodium exists in abundance during the biliary tract cancer, disrupting the balance and cellular toxicity of bile acids and inducing carcinogenesis through oxidative DNA damage and DNA mutation. Tauroursocholic acid (TUCA) sodium can be used for biliary tract cancer research.

7-MAD-MDCPT-AC-(s-cyclopropane) is a derivative of camptothecin. 7-MAD-MDCPT-AC-(s-cyclopropane) can be connected to monoclonal antibodies via linkers to form antibody-drug conjugate (ADC) molecules. 7-MAD-MDCPT-AC-(s-cyclopropane) can be used for cancer research.

N-Di(D-mannose)-PEG12-MC-VC-PAB-MMAE is a linker that can be synthesized to antibody-drug conjugate (ADC). N-Di(D-mannose)-PEG12-MC-VC-PAB-MMAE can be used for the study of cancer.

Crovozalpon (Compound 4) is an inhibitor of alplha-1-antitrypsin. Crovozalpon can be used as a prodrug. Crovozalpon can be studied in research for diseases associated with alplha-1-antitrypsin

GCS-12–6 is a potent Th2-selective NKT cell agonist targeting CD1d protein. GCS-12–6 is promising for research of autoimmune diseases (e.g., inflammatory bowel disease, multiple sclerosis).

ASI-222 is an aminosugar cardiac glycoside. ASI-222 can inhibit Na+/K+ ATPase and show positive inotropic effect. ASI-222 can be used for the research of cardiovascular disease.

EC-0225, a folate conjugate of two agents- one a potent microtubule inhibiting agent, and the second a DNA alkylating agent. EC-0225 inhibits the growth of folate receptor (FR)-positive KB cells with an IC50 of ~1 nM. EC-0225 can be selectively delivered to advanced FR-positive tumors without causing overt toxicity, such as lung carcinoma.

CP-394531 is an efficient and highly selective non-steroidal glucocorticoid receptor (GR) antagonist, with a Ki value of 0.1 nM. CP-394531 has a weak binding to androgen receptor (AR) (Ki = 130 nM), and has almost no effect on progesterone receptor (PR) and estrogen receptors (ERα, ERβ). CP-394531 completely blocks the half-maximal agonistic effect induced by Dexamethasone), with a Kif of 4.1 nM. CP-394531 can be used to study various diseases such as diabetes, obesity, depression, neurodegenerative diseases, glaucoma and Cushing's disease.

Nrf2 ligand-Linker Conjugate 2 is a synthesized Nrf2 ligand-linker conjugate that can be used for synthesis of PROTAC K-Ras Degrader-7. PROTAC K-Ras Degrader-7 is a potent K-Ras PROTAC degrader with anti-tumor activity.

Lipid OA2 dihydrochloride is an ionizable cationic lipid that can be used to prepare single-component lipid nanoparticles for siRNA delivery. Lipid OA2 dihydrochloride can effectively deliver SOCS1-siRNA to dendritic cells, silence the SOCS1 gene, and enhance their antigen-presenting ability and pro-inflammatory factor secretion capacity.

EP-51216 is a growth hormone agonist peptide. EP-51216 increases food intake. EP-51216 can be used in the research of eating disorders.

YL6113 is a potent and selective dual inhibitor of metallo-β-lactamases (MBLs) and serine-β-lactamases (SBLs). YL6113 shows inhibitory effect to MBLs, such as NDm-1, VIM-2, IMP-1, with IC50 values of 0.25, 27.16 and 3.55 μM. YL6113 shows inhibitory effect to SBLs, such as KPC-2, AmpC, OXA-48, with IC50 values of 0.2, 34.1 and 1.31 μM. YL6113 enhances the antibacterial efficacy of Meropenem against carbapenem-resistant Gram-negative bacteria. YL6113 can be used for the research of infection.

7-MAD-MDCPT TFA, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs).

7-MAD-MDCPT hydrochloride, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs).

Gly-7-MAD-MDCPT (Compound 4b) TFA is an anticancer agent. Gly-7-MAD-MDCPT TFA is a Camptothecin compound, which shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM.

Gly-7-MAD-MDCPT (Compound 4b) hydrochloride is an anticancer agent. Gly-7-MAD-MDCPT hydrochloride is a Camptothecin compound, which shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM.

Gly-Gly-Gly-PEG3-TCO TFA is a 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

(R)-BMS-986449 is the racemic mixture of BMS-986449. BMS-986449 is a CELMoD molecular glue and an IKZF2/IKZF4 degrader. BMS-986449 targets the degradation of transcription factors Helios (IKZF2) and Eos (IKZF4) in regulatory T (Treg) cells. BMS-986449 redirects the E3 ubiquitin ligase Cereblon to induce the degradation of Helios and Eos, reprogramming Treg cells and enhancing antitumor immunity. BMS-986449 is promising for research of advanced solid tumors.

ZnPcPs is a photosensitizer that generates ROS. ZnPcPs can be used to synthesize the photo-activated BRD4 degrader pZnPc-O3-JQ1.

Aβ1–42 aggregation inhibitor 3 (Compound 3b) is an acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor (IC50 values are 1.634 and 0.0285 μM, respectively). Aβ1–42 aggregation inhibitor 3 can inhibit the aggregation of Aβ1-42. Aβ1–42 aggregation inhibitor can be used in Alzheimer's disease (AD) research.

SLC-391 is a selective, orally active AXL inhibitor with an IC50 of 9.6 nM. SLC-391 has antiviral activity.

SM 10888 is a selective and orally active cholinesterase (ChE) inhibitor. SM 10888 can increase brain acetylcholine release. SM 10888 can be used for the research of neurological disease, such as Alzheimer's disease.

JBPOS-0101 is a phenyl carbamate compound. JBPOS-0101 exhibits neuroprotective and antiepileptic effects. JBPOS-0101 can attenuate the accumulation of Aβ in 5XFAD mouse brains and rescue the deficits in learning and memory. JBPOS-0101 can be used for the research of neurological disease, such as Alzheimer's disease (AD).

KARI 201 hydrochloride is a selective, brain penetrant pand competitive acid sphingomyelinase (ASM) inhibitor with an IC50 of 338.3?nM. KARI 201 hydrochloride is a ghrelin receptor agonist. KARI 201 hydrochloride improves neuropathological features of Alzheimer's disease.

Basivarsen linker is a linker used in Zeleciment basivarsen for coupling a TfR1-binding Fab Zeleciment) and an antisense oligonucleotide. Zeleciment basivarsen is an antibody-oligonucleotide conjugate (AOC) designed to target mutant nuclear myotonic dystrophy protein kinase (DMPK) RNA for RHase H-mediated degradation to correct splicing. It is used for the study of myotonic dystrophy type 1 (DM1).

Irafamdastat (BMS-986368) (Example 74) is a FAAH and MAGL inhibitor, with IC50s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect.